Discover

Back to filter

Related topics

WEBINAR: Recent Advancements In Neurodegenerative Biomarkers

Quanterix

Sep 6, 2021

Recent Advancements in Neurodegenerative Biomarkers: Progress Towards a Diagnostic Blood Test for Alzheimer’s Disease

How to Improve Your Viral Nucleic Acid Extraction Processes

Analytik Jena

Sep 6, 2021

High-Throughput Extraction with CyBio FeliX

Introducing New Aura 4.0 software

Spectral Instruments Imaging

Aug 31, 2021

With new features for both acquisition & analysis Aura Software enables you to capture and analyze your data quickly,...

Comparison of gamma and x-ray irradiation results

Precision X-Ray

Aug 12, 2021

Biological effects of Cs-137 and X-ray irradiators are comparable with regards to...

Hypoxia further exacerbates myopathy in broilers via alteration of satellite cell fate

COY laboratory products

Aug 2, 2021

Woody breast (WB) condition has created a variety of challenges for the global poultry...

High quality Bioluminescence and X-Ray analysis in lung squamous cell carcinoma

Spectral Instruments Imaging

Jul 21, 2021

Spectral Instruments Imaging provides unrivaled sensitivity for bioluminescence,...

Top 10 Pharma companies have chosen CYTEK for their flow cytometry facility

Cytek Biosciences

Jul 15, 2021

6 of Top 10 Pharma Companies (Based on total group revenues) have chosen CYTEK - full...

Webinar recording: Autofluorescence management - the power of Spectral Flow Cytometry

Cytek Biosciences

Jul 15, 2021

One of the key advantages of spectral flow cytometry is its ability to extract sample...

Webinar recording: Super-Resolution imaging of Chromatin organization in health and disease

ONI

Jul 9, 2021

Understanding how cells organize the array of components within their membranous confines can not only provide insight...

Show all topics (10)

Heterodimeric compounds with dual-targeting active against both HIV and tuberculosis.

Jun 4, 2018

Both HIV and Tuberculosis are considered to be one of the most dangerous infectious diseases in the world. Quite often these two pathogens work in synchrony, making the risk of patient´s death twice as high. To solve this problem researchers from the Engelhardt Institute of Molecular biology in Russia cooperated with the National Institute of Health in the USA. They created compounds with dual activity against both pathogens by creating a heterodimer based on nucleosides. These heterodimers have two active components with two different rates of release based on the speed of their hydrolysis. They tested five of such compounds on HIV and Tuberculosis strain MS-114, which is drug-resistance. Drug-resistance of tuberculosis is one of the main problems in the treatment nowadays.

The compounds were judged based on the ability to inhibit these pathogens. Additionally, a testing on the host tissue was done using NovoCyte. The researchers tested the viability of mammalian lymphoid tissue after treatment. The results show that the heterodimers are non-toxic and non-static towards the cells while maintaining the potency against the pathogens. So far the compound was tested in vivo and ex vitro and seem to be a very promising solution. These results bring interesting insight and novel approach toward treatment of both HIV and Tuberculosis.

Want to know more?

Scientific paper
Application

Related technologies: Conventional flow cytometry

Brand profile

Agilent technologies

Agilent provides xCELLigence impedance-based, label-free, real time cell analysis system and NovoCyte flow cytometers.

Related products

The best in class personalized flow cytometer

show detail

We supply and support Life-Science Technologies in the territory of Central and Eastern Europe.

Czech Republic

Slovakia

Hungary

Poland

Croatia

Slovenia

Serbia

Romania

Bulgaria

Latvia

Lithuania

Estonia

Russia

Ukraine

Belarus

Turkey